FDA Certification Does Not Shield Generic Drug Maker from Suit
Generic drug manufacturers are not insulated from lawsuits by a Food and Drug Administration (FDA) approval process that certifies such drugs as the “bioequivalent” of their brand-name predecessors, a federal judge in Philadelphia has ruled.
This premium content is locked for LawJournalNewsletters subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.